云南省文山州银屑病患者血清C_3水平与代谢综合征相关性分析
|
摘要
目的:探讨云南省文山州银屑病患者血清补体C_3与代谢综合征(MS)间的相关性。方法:选取云南省文山州728例银屑病患者(银屑病组)及756名体检者(健康对照组),比较银屑病患者与健康对照组MS发生率及补体C_3水平,进一步对银屑病合并和不合并MS患者的临床资料、补体C_3水平进行比较,分析影响合并MS的银屑病患者补体C_3水平的相关因素。结果:银屑病组患者高血糖及血脂异常发生率均高于健康对照组(P<0.05),MS发生率高于健康对照组(P=0.003)。饮酒是云南省文山州银屑病患者合并MS的高危因素(P=0.013)。与不合并MS的银屑病患者相比,合并MS的银屑病患者血清补体C_3更高(P=0.015),且C_3与体质指数(BMI)、银屑病面积和严重程度指数(PASI)正相关(P<0.05),与寻常型和关节病型银屑病相关(P<0.05)。结论:云南省文山州银屑病患者更易发生MS;血清补体C_3水平与MS的发生相关,且与银屑病病情严重程度相关,在寻常型和关节病型银屑病患者中尤其较高。
Objective: To investigate the association between serum complement 3(C_3) and metabolic syndrome(MS) in psoriasis patients from Wenshan County of Yunnan Province. Methods: A total of seven hundred and twenty eight psoriasis patients(psoriasis group) and seven hundred and fifty six healthy controls(healthy group) were enrolled from Wenshan County of Yunnan Province. The incidence of MS and C_3 level were compared between the two groups. The clinical features and C_3 level of psoriasis patients with and without MS were also compared. The related factors of C_3 level in psoriasis patients combined with MS were analyzed. Results: The incidences of high fast blood glucose and lipid disorder in the psoriasis group were higher than those in the control group(P<0.05). And the incidence of MS was higher in the psoriasis group than that in the control group(P=0.003). Drinking was a risk factor for comorbidity of psoriasis and MS in patients from Yunnan Wenshan(P=0.013). The serum C_3 level of psoriasis patients combined with MS was statistically higher than that in patients without MS(P=0.015). And C_3 level was positively correlated with body mass index(BMI), psoriasis area and severity index(P<0.05). And there were significant correlations between C_3 level and psoriasis vulgaris and psoriasis arthropathica(P<0.05). Conclusions: In Wenshan County of Yunnan Province, psoriasis patients are more likely to have MS. C_3 level is significantly correlated with MS and the severity of psoriasis, especially high in patients with psoriasis vulgaris or arthropathica.
Objective: To investigate the association between serum complement 3(C_3) and metabolic syndrome(MS) in psoriasis patients from Wenshan County of Yunnan Province. Methods: A total of seven hundred and twenty eight psoriasis patients(psoriasis group) and seven hundred and fifty six healthy controls(healthy group) were enrolled from Wenshan County of Yunnan Province. The incidence of MS and C_3 level were compared between the two groups. The clinical features and C_3 level of psoriasis patients with and without MS were also compared. The related factors of C_3 level in psoriasis patients combined with MS were analyzed. Results: The incidences of high fast blood glucose and lipid disorder in the psoriasis group were higher than those in the control group(P<0.05). And the incidence of MS was higher in the psoriasis group than that in the control group(P=0.003). Drinking was a risk factor for comorbidity of psoriasis and MS in patients from Yunnan Wenshan(P=0.013). The serum C_3 level of psoriasis patients combined with MS was statistically higher than that in patients without MS(P=0.015). And C_3 level was positively correlated with body mass index(BMI), psoriasis area and severity index(P<0.05). And there were significant correlations between C_3 level and psoriasis vulgaris and psoriasis arthropathica(P<0.05). Conclusions: In Wenshan County of Yunnan Province, psoriasis patients are more likely to have MS. C_3 level is significantly correlated with MS and the severity of psoriasis, especially high in patients with psoriasis vulgaris or arthropathica.
引文
[1] NEWGARD C B.Metabolomics and metabolic diseases:where do we stand?[J].Cell Metab,2017,25(1):43-56.
[2] 王强,池丽俏.钙泊三醇倍他米松乳膏联合窄谱中波紫外线治疗稳定期寻常型银屑病的疗效分析[J].中国临床医学,2014,21(5):586-588.
[3] SHIBA M,KATO T,FUNASAKO M,et al.Correction:Association between psoriasis vulgaris and coronary heart disease in a hospital-based population in Japan[J].PLoS One,2016,11(6):e0158699.
[4] WINER S,CHAN Y,PALTSER G,et al.Normalization of obesity-associated insulin resistance through immunotherapy[J].Nat Med,2009,15(8):921-929.
[5] SINGH S,YOUNG P,ARMSTRONG A W.An update on psoriasis and metabolic syndrome:A meta-analysis of observational studies[J].PLoS One,2017,12(7):e0181039.
[6] DING X,WANG T,SHEN Y,et al.Prevalence of psoriasis in China:a population-based study in six cities[J].Eur J Dermatol,2012,22(5):663-667.
[7] ARMSTRONG A W,HARSKAMP C T,ARMSTRONG E J.Psoriasis and metabolic syndrome:a systematic review and meta-analysis of observational studies[J].J Am Acad Dermatol,2013,68(4):654-662.
[8] 戴莎,王秀丽,宋心葵,等.银屑病患者410例合并代谢综合征分析[J].中国皮肤性病学杂志,2012,26(8):700-701,756.
[9] LANGAN S M,SEMINARA N M,SHIN D B,et al.Prevalence of metabolic syndrome in patients with psoriasis:a population-based study in the United Kingdom[J].J Invest Dermatol,2012,132(3 Pt 1):556-562.
[10] GISONDI P,FOSTINI A C,FOSSà I,et al.Psoriasis and the metabolic syndrome[J].Clin Dermatol,2018,36(1):21-28.
[11] ACEVEDO F,HAMMAR H.Complement C3 proteins in psoriasis[J].Br J Dermatol,1989,121(3):329-335.
[12] ROCHA-PEREIRA P,SANTOS-SILVA A,REBELO I,et al.The inflammatory response in mild and in severe psoriasis[J].Br J Dermatol,2004,150(5):917-928.
[13] REINDL J,PESEK J,KRüGER T,et al.Proteomic biomarkers for psoriasis and psoriasis arthritis[J].J Proteomics,2016,140:55-61.
[14] SCHONTHALER H B,GUINEA-VINIEGRA J,WCULEK S K,et al.S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3[J].Immunity,2013,39(6):1171-1181.
[15] ULU?KAN ?,WAGNER E F.Role of IL-17A signalling in psoriasis and associated bone loss[J].Clin Exp Rheumatol,2016,34(4 Suppl 98):17-20.
[16] OHSAWA I,INOSHITA H,ISHII M,et al.Metabolic impact on serum levels of complement component 3 in Japanese patients[J].J Clin Lab Anal,2010,24(2):113-118.
[17] 孙祖凤,罗阳,韩悦,等.银屑病患者血清C3的表达及其与银屑病的相关性[J].中国麻风皮肤病杂志,2017,33(10):599-602.
[18] URSINI F,D’ANGELO S,RUSSO E,et al.Complement C3 is the strongest predictor of whole-body insulin sensitivity in psoriatic arthritis[J].PLoS One,2016,11(9):e0163464.
[19] TORRES T,BETTENCOURT N,MENDON?A D,et al.Complement C3 as a marker of cardiometabolic risk in psoriasis[J].Arch Dermatol Res,2014,306(7):653-660.
[2] 王强,池丽俏.钙泊三醇倍他米松乳膏联合窄谱中波紫外线治疗稳定期寻常型银屑病的疗效分析[J].中国临床医学,2014,21(5):586-588.
[3] SHIBA M,KATO T,FUNASAKO M,et al.Correction:Association between psoriasis vulgaris and coronary heart disease in a hospital-based population in Japan[J].PLoS One,2016,11(6):e0158699.
[4] WINER S,CHAN Y,PALTSER G,et al.Normalization of obesity-associated insulin resistance through immunotherapy[J].Nat Med,2009,15(8):921-929.
[5] SINGH S,YOUNG P,ARMSTRONG A W.An update on psoriasis and metabolic syndrome:A meta-analysis of observational studies[J].PLoS One,2017,12(7):e0181039.
[6] DING X,WANG T,SHEN Y,et al.Prevalence of psoriasis in China:a population-based study in six cities[J].Eur J Dermatol,2012,22(5):663-667.
[7] ARMSTRONG A W,HARSKAMP C T,ARMSTRONG E J.Psoriasis and metabolic syndrome:a systematic review and meta-analysis of observational studies[J].J Am Acad Dermatol,2013,68(4):654-662.
[8] 戴莎,王秀丽,宋心葵,等.银屑病患者410例合并代谢综合征分析[J].中国皮肤性病学杂志,2012,26(8):700-701,756.
[9] LANGAN S M,SEMINARA N M,SHIN D B,et al.Prevalence of metabolic syndrome in patients with psoriasis:a population-based study in the United Kingdom[J].J Invest Dermatol,2012,132(3 Pt 1):556-562.
[10] GISONDI P,FOSTINI A C,FOSSà I,et al.Psoriasis and the metabolic syndrome[J].Clin Dermatol,2018,36(1):21-28.
[11] ACEVEDO F,HAMMAR H.Complement C3 proteins in psoriasis[J].Br J Dermatol,1989,121(3):329-335.
[12] ROCHA-PEREIRA P,SANTOS-SILVA A,REBELO I,et al.The inflammatory response in mild and in severe psoriasis[J].Br J Dermatol,2004,150(5):917-928.
[13] REINDL J,PESEK J,KRüGER T,et al.Proteomic biomarkers for psoriasis and psoriasis arthritis[J].J Proteomics,2016,140:55-61.
[14] SCHONTHALER H B,GUINEA-VINIEGRA J,WCULEK S K,et al.S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3[J].Immunity,2013,39(6):1171-1181.
[15] ULU?KAN ?,WAGNER E F.Role of IL-17A signalling in psoriasis and associated bone loss[J].Clin Exp Rheumatol,2016,34(4 Suppl 98):17-20.
[16] OHSAWA I,INOSHITA H,ISHII M,et al.Metabolic impact on serum levels of complement component 3 in Japanese patients[J].J Clin Lab Anal,2010,24(2):113-118.
[17] 孙祖凤,罗阳,韩悦,等.银屑病患者血清C3的表达及其与银屑病的相关性[J].中国麻风皮肤病杂志,2017,33(10):599-602.
[18] URSINI F,D’ANGELO S,RUSSO E,et al.Complement C3 is the strongest predictor of whole-body insulin sensitivity in psoriatic arthritis[J].PLoS One,2016,11(9):e0163464.
[19] TORRES T,BETTENCOURT N,MENDON?A D,et al.Complement C3 as a marker of cardiometabolic risk in psoriasis[J].Arch Dermatol Res,2014,306(7):653-660.